Clin Res Hepatol Gastroenterol
October 2023
There are no published data on the use of odevixibat, a selective ileal bile acid transporter (IBAT) inhibitor, in children with tight junction protein 2 (TJP2) deficiency (also named as PFIC-4). We describe a case series of five children treated with odevixibat. After treatment, serum bile acids (sBA) decreased compared to baseline [mean value: 244 (±125), vs 38 (±34) µmol/L; p = 0.
View Article and Find Full Text PDFBackground: The natural history of ulcerative proctitis (UP) has been poorly investigated in children.
Aims: We aimed to compare the disease course of children with UP at diagnosis to the other locations and to identify extension predictors.
Methods: This was a multicenter, observational study carried out from data prospectively entered in the SIGENP-IBD-Registry.
Improving the quality of life (QoL) is crucial in the management of pediatric inflammatory bowel disease (IBD). We aimed to (1) Validate the IMPACT-III questionnaire in Italian IBD children; (2) explore factors associated to QoL in pediatric IBD. Internal consistency, concurrent validity, discriminant validity and reproducibility of the Italian version of the IMPACT-III questionnaire was measured in IBD children/adolescents in 8 centers.
View Article and Find Full Text PDF